Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Placebo-controlled, Double-blind, Randomized Trial to Evaluate the Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Subjects With Newly Diagnosed Sputum Smear-positive Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB).
Brief Summary: The objective of this study is to demonstrate that the antibacterial activity of TMC207 is better than placebo when added to a standardized Background Regimen (BR) for treatment of multi-drug resistant TB. Also safety and tolerability will be evaluated.


Options:
A: Arm Label: Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg); Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin (M), Drug: Pretomid (Pa), Drug: Pyrazinamide (Z) | Arm Label: Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg); Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin (M), Drug: Pretomid (Pa), Drug: Pyrazinamide (Z) | Arm Label: Drug Sensitive: Rifafour; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rifafour | Arm Label: Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg); Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin (M), Drug: Pretomid (Pa), Drug: Pyrazinamide (Z) | Intervention Type: DRUG; Name: Moxifloxacin (M); Assigned to Arm(s): Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg), Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg), Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg) | Intervention Type: DRUG; Name: Pretomid (Pa); Assigned to Arm(s): Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg), Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg), Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg) | Intervention Type: DRUG; Name: Pyrazinamide (Z); Assigned to Arm(s): Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg), Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg), Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg) | Intervention Type: DRUG; Name: Rifafour; Assigned to Arm(s): Drug Sensitive: Rifafour
B: Arm Label: TMC207 Stage 1; Type: EXPERIMENTAL; Interventions: Drug: TMC207, Drug: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis) | Arm Label: Placebo Stage 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis) | Arm Label: TMC207 Stage 2; Type: EXPERIMENTAL; Interventions: Drug: TMC207, Drug: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis) | Arm Label: Placebo Stage 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis) | Intervention Type: DRUG; Name: TMC207; Assigned to Arm(s): TMC207 Stage 1, TMC207 Stage 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Stage 1, Placebo Stage 2 | Intervention Type: DRUG; Name: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis); Assigned to Arm(s): Placebo Stage 1, Placebo Stage 2, TMC207 Stage 1, TMC207 Stage 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isoniazid, Rifampin, Pyrazinamide, Ethambutol | Intervention Type: DRUG; Name: Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Isoniazid, Rifampin, Pyrazinamide, Ethambutol; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: Gatifloxacin combined regimen; Assigned to Arm(s): N/A

Answer: B